503A vs 503B Compounding Pharmacies
503A pharmacies compound patient-specific prescriptions under state board of pharmacy oversight. 503B outsourcing facilities register with the FDA and may produce larger batches without patient-specific prescriptions. Both follow FDA Section 503 of the Federal Food, Drug, and Cosmetic Act, and the right setting depends on how a medication will be dispensed.
What's being compared
State-licensed pharmacy compounding patient-specific prescriptions.
FDA-registered facility that may compound larger batches under cGMP.
Side-by-side comparison
| Attribute | 503A | 503B |
|---|---|---|
| Primary regulator | State board of pharmacy (with FDA oversight under 503A). | FDA, with cGMP-style oversight under 503B. |
| Patient-specific prescription required | Yes — each compounded preparation requires a patient-specific prescription. | Not always — 503B facilities may compound for office use without a patient-specific prescription. |
| Batch authority | Limited; may compound small quantities in anticipation of patient-specific prescriptions per state rules. | Authorized to compound larger batches that may be sold to clinics for office stock. |
| Manufacturing standards | USP standards (e.g. <795>, <797>, <800>) per state requirements. | cGMP-style requirements as enforced by the FDA. |
| Registration | Licensed by state boards of pharmacy. | Registered as outsourcing facilities with the FDA. |
| Typical preparation forms | Patient-specific compounded preparations: injectable vials, syringes, oral troches or capsules, nasal sprays, and topicals tailored per prescription. | Larger-batch compounded preparations: pre-filled syringes, multi-dose vials, and ready-to-administer formats supplied to clinics. |
| Oversight evidence framework | USP General Chapters (e.g. <795>, <797>, <800>) plus state-board inspection records form the published oversight framework. | FDA cGMP inspections, 483 observations, warning letters, and the FDA's published 503B registered facility list form the public oversight record. |
| Typical use case | Tailored compounded preparations dispensed to a specific patient on a specific prescription. | Larger-batch compounded preparations for clinic office stock or hospital systems. |
| Where Regen Therapy fits | Regen Therapy works with 503A and 503B pharmacy partners (including Wells Pharmacy Network) for patient-specific prescriptions. | Regen Therapy works with 503A and 503B pharmacy partners (including Wells Pharmacy Network) when a 503B pathway is appropriate. |
Which one might fit?
Use the framings below as orientation only. The right therapy is determined by your prescribing clinician based on history, lab work, and the specifics of your situation.
A 503A pharmacy is the standard pathway — every preparation is prescribed and labeled for a specific patient.
A 503B outsourcing facility is the pathway designed for larger batches that may be supplied without a patient-specific prescription.
Ask the prescribing clinician or the dispensing pharmacy. Both pathways are legitimate when used as intended; the right setting depends on the clinical workflow.
Talk to a clinician about which fits
Every Regen Therapy protocol is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network only after evaluation. Start with a brief intake to see what makes sense for your situation.
Frequently asked questions
Is one safer than the other?
Both are regulated, but in different ways. 503A pharmacies operate under state boards of pharmacy with FDA oversight; 503B outsourcing facilities follow cGMP-style standards under direct FDA registration. Neither category is inherently safer — both follow rigorous standards when used as intended.
Are compounded medications FDA-approved?
No. Compounded medications, whether prepared by a 503A pharmacy or a 503B outsourcing facility, are not FDA-approved finished products. They are compounded under specific pathways defined in Section 503 of the FD&C Act.
Why are GLP-1 medications often compounded?
Compounded GLP-1 medications have been prepared by 503A and 503B pharmacies during shortages of the FDA-approved finished products. Whether a compounded version is appropriate is a clinical decision made on a per-patient basis.
Does Regen Therapy use 503A or 503B partners?
Both, depending on the protocol and the clinical workflow. Wells Pharmacy Network is one of Regen Therapy's compounding partners. Each prescription is reviewed by a licensed clinician.
Do I need a prescription either way?
Compounded medications dispensed to you as a patient require a patient-specific prescription. A 503B outsourcing facility may also produce batches for clinic office stock, which is administered under that clinic's clinician oversight.
Where can I read the underlying law?
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013, define the two compounding pathways.